Source 1primary paper2025MED
Toolkit/VNAR-based CAR-T cells targeting PD-L1
VNAR-based CAR-T cells targeting PD-L1
Taxonomy: Mechanism Branch / Architecture. Workflows sit above the mechanism and technique branches rather than replacing them.
Summary
VNAR-based CAR-T cells targeting PD-L1 demonstrated strong anti-tumor effects in preclinical assays
Usefulness & Problems
Why this is useful
This construct pattern uses a shark VNAR as the targeting domain in CAR-T cells directed against PD-L1. The abstract reports strong anti-tumor effects in preclinical assays.; preclinical anti-tumor cell therapy
Source:
This construct pattern uses a shark VNAR as the targeting domain in CAR-T cells directed against PD-L1. The abstract reports strong anti-tumor effects in preclinical assays.
Source:
preclinical anti-tumor cell therapy
Problem solved
It provides a way to couple VNAR target recognition to cellular anti-tumor effector function.; targeted anti-tumor activity against PD-L1-expressing tumors
Source:
It provides a way to couple VNAR target recognition to cellular anti-tumor effector function.
Source:
targeted anti-tumor activity against PD-L1-expressing tumors
Problem links
targeted anti-tumor activity against PD-L1-expressing tumors
LiteratureIt provides a way to couple VNAR target recognition to cellular anti-tumor effector function.
Source:
It provides a way to couple VNAR target recognition to cellular anti-tumor effector function.
Taxonomy & Function
Primary hierarchy
Mechanism Branch
Architecture: A reusable architecture pattern for arranging parts into an engineered system.
Techniques
Functional AssayTarget processes
No target processes tagged yet.
Implementation Constraints
cofactor dependency: cofactor requirement unknownencoding mode: genetically encodedimplementation constraint: context specific validationoperating role: actuator
Its use requires CAR-T cell engineering and a PD-L1-targeting design.; requires CAR-T cell engineering; requires PD-L1 targeting context
Independent follow-up evidence is still limited. Validation breadth across biological contexts is still narrow. Independent reuse still looks limited, so the evidence base may be fragile. No canonical validation observations are stored yet, so context-specific performance remains under-specified.
Validation
Cell-freeBacteriaMammalianMouseHumanTherapeuticIndep. Replication
Supporting Sources
Ranked Claims
VNAR-based CAR-T cells targeting PD-L1 demonstrated strong anti-tumor effects in preclinical assays.
VNARs have small size, simple structure, and exceptional stability.
VNARs can access cryptic epitopes that are inaccessible to traditional antibodies.
VNARs have advantages over traditional antibodies and camelid VHHs in targeting difficult-to-reach sites and environments.
The TXB2 VNAR platform allows efficient, non-invasive transport of biologics across the blood-brain barrier.
VNARs show resistance to extreme pH, temperature, and proteolytic environments, supporting use in demanding biomedical settings such as ocular and intestinal applications.
VNAR-B2 reduced tumor growth in mouse models.
VNAR-B2 blocks PD-L1/PD-1 interactions.
Humanization and half-life extension are key translational challenges for clinical application of VNARs.
Approval Evidence
1 source1 linked approval claimfirst-pass slug vnar-based-car-t-cells-targeting-pd-l1
VNAR-based CAR-T cells targeting PD-L1 demonstrated strong anti-tumor effects in preclinical assays
Source:
application performancesupports
VNAR-based CAR-T cells targeting PD-L1 demonstrated strong anti-tumor effects in preclinical assays.
Source:
Comparisons
Source-stated alternatives
The abstract places this approach within a broader comparison against traditional antibodies and camelid VHH-based targeting formats.
Source:
The abstract places this approach within a broader comparison against traditional antibodies and camelid VHH-based targeting formats.
Source-backed strengths
strong anti-tumor effects in preclinical assays
Source:
strong anti-tumor effects in preclinical assays
Compared with CheRiff
VNAR-based CAR-T cells targeting PD-L1 and CheRiff address a similar problem space.
Shared frame: same top-level item type
Strengths here: looks easier to implement in practice.
Compared with intermolecular disulfide-based light switch
VNAR-based CAR-T cells targeting PD-L1 and intermolecular disulfide-based light switch address a similar problem space.
Shared frame: same top-level item type
Strengths here: looks easier to implement in practice.
VNAR-based CAR-T cells targeting PD-L1 and Pyr-NHS-functionalised 3D graphene foam electrode biosensor address a similar problem space.
Shared frame: same top-level item type
Ranked Citations
- 1.